The company, which is headquartered in Los Angeles, is seeking to develop and commercialize new therapeutics to fight cancer using the immune system.
Singh will present at the Cowen and Company's 32nd Annual Health Care symposium taking place in Boston, Massachusetts today at 2:10 p.m. The event will be on the fourth floor at the Salon C of the Marriot Hotel.
The presentation will be webcast here: wsw.com/webcast/cowen6/imuc/
ImmunoCellular's lead product candidate ICT-107 is currently in a randomized phase II trial at multiple centres in the U.S. ICT-107 is a dendritic cell-based vaccine that works by activating a patient's immune system against specific tumour associated antigens for glioblastoma multiforme, an aggressive type of brain cancer.
This is done by removing dendritic cells from a patient, loading them with the tumour-related antigens, and re-injecting them back into the patient's body to trigger an immune response against cancer cells exhibiting these antigens.
Rather than simply targeting a single tumour-specific antigen, ImmunoCellular's vaccine pursues multiple different antigens found on cancer stem cells.
Cancer stem cells are thought to be the originators of common tumour cells, and lead to cancer's re-growth after chemotherapy. It is believed that destroying the cancer stem cells will allow for longer survival, without relapse.
The company's share price rose 3.27 percent to $2.84 on the OTC, or over-the-counter market Monday afternoon.